587-26-8

Treatment of hyperphosphatae mia in patients with end stage renal disease.

Fosrenol (Shire).

Notclassified

Lanthanum Carbonate inhibits phosphate absorption from the intestine and lowers the phosphate levels in the blood. Lanthanum Carbonate inhibits phosphate absorption from the intestine and lowers the phosphate levels in the blood.

#N/A

Nausea, Vomiting, Abdominal pain

Lanthanum carbonate is an ideal phosphate binder. It prevents the adsorption of dietary phosphate by forming insoluble lanthanum phosphate. It has been reported that lanthanum carbonate binds phosphate optimally at pH 3–5, while retaining binding activity at pH 1–7. In vitro, studies suggest that the efficacy of lanthanum phosphate is comparable to that of aluminium compounds in binding with phosphate. The FDA has approved using lanthanum carbonate as a phosphate binder for renal failure patients.

Potentially hazardous interactions with other drugs Antibacterials: possibly reduces absorption of quinolones - give at least 2 hours before or 4 hours after lanthanum. Antifungals: absorption of ketoconazole reduced - give at least 2 hours apart. Antimalarials: absorption of chloroquine and hydroxychloroquine possibly reduced - give at least 2 hours apart. Thyroid hormones: reduces absorption of levothyroxine - give at least 2 hours apart

Lanthanum carbonate is poorly absorbed from the gastrointestinal tract, with an absolute oral bioavailability of less than 1%. The small fraction that is absorbed is more than 99% bound to plasma proteins and is widely distributed in the tissues, particularly the bones, the liver, and the gastrointestinal tract. Lanthanum is not metabolised. It is excreted mainly in the faeces with only around 0.000031% of an oral dose excreted via the urine in healthy subjects (renal clearance approximately 1 mL/ min, representing <2% of total plasma clearance)